Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis' Cosentyx Goes Head-To-Head With Humira

Executive Summary

With the initiation of EXCEED and SURPASS, Novartis is aiming to challenge Humira’s status as the preferred first-line biologic for ankylosing spondylitis and psoriatic arthritis.


Related Content

Lilly's Taltz Gets Closer To A Level Playing Field With Novartis' Cosentyx
Novartis Allays Concerns Over Cosentyx Sales Miss
Positive Spondylitis Phase III Brings Lilly's Taltz Closer To Cosentyx's Label
Pharma Q4 Results Preview: J&J, Novartis, Celgene, Biogen & AbbVie
Novartis Champions Cosentyx With More Long-Term Psoriasis Data
Humira Biosimilar: Boehringer Faces Same Launch Hurdles As Amgen


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts